Entry Rationale
The current price (16.6) is significantly above the previous day's low (14.86) and is showing upward pressure as it approaches the day's high (17.4).
BrainsWay beats top-line estimates; raises FY2026 outlook
BrainsWay exceeded top estimates and raised its FY2026 outlook.
The current price (16.6) is significantly above the previous day's low (14.86) and is showing upward pressure as it approaches the day's high (17.4).
Take profit if the price reaches $17.29, and cut loss if it reaches $14.14.
The RSI(14) is at 37.3, indicating a position close to the neutral zone and suggesting slight weakness, but it is not oversold. The moving averages are in a positive alignment, with the short-term moving average positioned above the medium- to long-term moving averages, supporting an upward trend. The trading volume is at 0.85 times the 20-day average, which is below average, and the recent 7-day volatility shows a slight decline of -1.6%.
The actual return was 12.7%, surpassing the expected return of 4.2%, resulting in an OVERHIT designation. The news accurately identified positive factors such as exceeding top estimates and an upward revision of the FY2026 outlook. Technically, the alignment of moving averages and the current price being above the previous day's low also suggested potential for an increase. However, considering that the trading volume was below average and the RSI remained in the neutral zone, the upward potential was estimated conservatively. In reality, buying pressure was stronger than anticipated, leading to a significant exceedance of the target price.
In the event of similar positive news in the future, we will additionally verify whether there is an increase in trading volume. If the trading volume exceeds the average, we plan to raise the target price or utilize a trailing stop to expand profits. Furthermore, even if the moving averages are in a bullish alignment and the RSI is neutral, we will adjust our strategy to increase our position if the upward trend is strong.